At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,250 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study to Identify BEnefits After 24 Weeks of NEBILET®(Nebivolol) Administration For Essential hypertensIon Patients With Various Co-morbidities and Treatment Environments in KOREA.
In Brief
An observational study for Essential Hypertension. Completed, enrolled 3,250 participants across 1 site.
Detailed Summary
The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
Primary CompletionMar 2017
First PostedFeb 2019
TodayJul 2026
First PostedFeb 20, 2019
Enrollment StartJul 1, 2015
Primary CompletionMar 23, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.4 years ago